CureVac's Potential Has Wall Street Sending Mixed Signals

While there seems general acknowledgment that CureVac (NASDAQ:CVAC) can still win a seat at the COVID-19 vaccine table -- and arguably, take up a lot of room at that table -- Wall Street remains largely unimpressed by the biotech at the moment.